Cargando…

Long-acting beta-agonists in the management of chronic obstructive pulmonary disease: current and future agents

Chronic obstructive pulmonary disease (COPD) is characterized by progressive airflow limitation and debilitating symptoms. For patients with moderate-to-severe COPD, long-acting bronchodilators are the mainstay of therapy; as symptoms progress, guidelines recommend combining bronchodilators from dif...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tashkin, Donald P, Fabbri, Leonardo M
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2010
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2991288/ https://www.ncbi.nlm.nih.gov/pubmed/21034447 http://dx.doi.org/10.1186/1465-9921-11-149

Ejemplares similares

Once-daily long-acting beta-agonists for chronic obstructive pulmonary disease: an indirect comparison of olodaterol and indacaterol
por: Roskell, Neil S, et al.
Publicado: (2014)

Ultra Long-Acting β-Agonists in Chronic Obstructive Pulmonary Disease
por: Burkes, Robert M, et al.
Publicado: (2020)

Effect of Adding Inhaled Corticosteroid to Long-Acting Muscarinic Antagonist/Long-Acting Beta-Agonist Therapy Among Patients With Chronic Obstructive Pulmonary Disease
por: Yuasa, Mizuki, et al.
Publicado: (2021)

Formoterol for the Treatment of Chronic Obstructive Pulmonary Disease
por: Tashkin, Donald P
Publicado: (2020)

Combination bronchodilator therapy in the management of chronic obstructive pulmonary disease
por: Tashkin, Donald P, et al.
Publicado: (2013)

Inhaled glycopyrrolate for the treatment of chronic obstructive pulmonary disease
por: Tashkin, Donald P, et al.
Publicado: (2018)

Long-acting β(2)-agonists (LABA) in chronic obstructive pulmonary disease: efficacy and safety
por: Rossi, Andrea, et al.
Publicado: (2008)

The safety of long-acting β(2)-agonists in the treatment of stable chronic obstructive pulmonary disease
por: Decramer, Marc L, et al.
Publicado: (2013)

Cardiovascular events and all‐cause mortality in patients with chronic obstructive pulmonary disease using olodaterol and other long‐acting beta2‐agonists
por: Rebordosa, Cristina, et al.
Publicado: (2022)

Defining Disease Modification in Chronic Obstructive Pulmonary Disease
por: Halpin, David M.G., et al.
Publicado: (2009)

Role of eosinophils in airway inflammation of chronic obstructive pulmonary disease
por: Tashkin, Donald P, et al.
Publicado: (2018)

Age of Initiating Smoking: An Independent Predictor of Chronic Obstructive Pulmonary Disease in Later Life
por: Tashkin, Donald P.
Publicado: (2023)

Inhaled corticosteroids for chronic obstructive pulmonary disease: what is their role in therapy?
por: Tashkin, Donald P, et al.
Publicado: (2018)

Long-acting beta-agonists reduce mortality of patients with severe and very severe chronic obstructive pulmonary disease: a propensity score matching study
por: Horita, Nobuyuki, et al.
Publicado: (2013)

Marijuana Use as a Risk Factor for Chronic Obstructive Pulmonary Disease: Not There Yet
por: Tashkin, Donald P., et al.
Publicado: (2023)

Long-acting antimuscarinic therapy in patients with chronic obstructive pulmonary disease receiving beta-blockers
por: Chapman, Kenneth R., et al.
Publicado: (2021)

The benefits of combined treatment with corticosteroids and long-acting beta agonists
por: Singh, Dave
Publicado: (2006)

Long-Acting Beta Agonists Enhance Allergic Airway Disease
por: Knight, John M., et al.
Publicado: (2015)

Longitudinal inspiratory capacity changes in chronic obstructive pulmonary disease
por: Celli, Bartolome R, et al.
Publicado: (2012)

The efficacy and safety of additional treatment with short-acting muscarinic antagonist combined with long-acting beta-2 agonist in stable patients with chronic obstructive pulmonary disease: A systematic review and meta-analysis
por: Tanimura, Kazuya, et al.
Publicado: (2023)

The role of long-acting muscarinic antagonist/long-acting β agonist fixed-dose combination treatment for chronic obstructive pulmonary disease in China: a narrative review
por: Zhou, Ji’an, et al.
Publicado: (2021)

A randomized controlled trial of long-acting muscarinic antagonist and long-acting β2 agonist fixed-dose combinations in patients with chronic obstructive pulmonary disease
por: Muraki, Masato, et al.
Publicado: (2021)

A Genome-wide analysis of the response to inhaled beta2-agonists in Chronic Obstructive Pulmonary Disease
por: Hardin, Megan, et al.
Publicado: (2015)

Comparative efficacy of long-acting β2-agonists as monotherapy for chronic obstructive pulmonary disease: a network meta-analysis
por: Donohue, James F, et al.
Publicado: (2017)

Management of Asthma and Chronic Obstructive Pulmonary Disease with Combination Inhaled Corticosteroids and Long-Acting β-Agonists: A Review of Comparative Effectiveness Research
por: Mapel, Douglas W., et al.
Publicado: (2014)

Passive Monitoring of Short-Acting Beta-Agonist Use via Digital Platform in Patients With Chronic Obstructive Pulmonary Disease: Quality Improvement Retrospective Analysis
por: Chen, Jessica, et al.
Publicado: (2019)

Comparing Randomized Controlled Trials and Real-World Studies in Chronic Obstructive Pulmonary Disease Pharmacotherapy
por: Tashkin, Donald P, et al.
Publicado: (2020)

Prescription Patterns of New Use of Fixed-Dose Combination Inhalers in Patients with Chronic Obstructive Pulmonary Disease: Long-Acting β2 Agonists Plus Long-Acting Muscarinic Antagonists versus Long-Acting β2 Agonists Plus Inhaled Corticosteroids
por: Liao, Pei-An, et al.
Publicado: (2023)

Efficacy and safety of the long-acting β(2)-agonist olodaterol over 4 weeks in Japanese patients with chronic obstructive pulmonary disease
por: Ichinose, Masakazu, et al.
Publicado: (2015)

Risk of pneumonia with inhaled corticosteroid/long-acting β2 agonist therapy in chronic obstructive pulmonary disease: a cluster analysis
por: DiSantostefano, Rachael L, et al.
Publicado: (2014)

Targeting the Small Airways with Inhaled Corticosteroid/Long-Acting Beta Agonist Dry Powder Inhalers: A Functional Respiratory Imaging Study
por: Watz, Henrik, et al.
Publicado: (2021)

Impact of beta2-agonists, beta-blockers, and their combination on cardiac function in elderly male patients with chronic obstructive pulmonary disease
por: Zeng, Long-Huan, et al.
Publicado: (2013)

Paradoxical Bronchoconstriction with Short-Acting Beta Agonist
por: Magee, Jared S., et al.
Publicado: (2018)

Long acting β(2 )agonists for stable chronic obstructive pulmonary disease with poor reversibility: a systematic review of randomised controlled trials
por: Husereau, Don, et al.
Publicado: (2004)

Therapeutic preferences and factors determining the use of inhaled corticosteroids with long-acting β(2)-agonists in patients with asthma and chronic obstructive pulmonary disease
por: Olszanecka-Glinianowicz, Magdalena, et al.
Publicado: (2020)

Effects of Roflumilast on Patients with Chronic Obstructive Pulmonary Disease Treated with Inhaled Corticosteroid/Long-Acting β2 Agonist: A Meta-analysis
por: Zeng, Shasha, et al.
Publicado: (2022)

Changing patterns in long-acting bronchodilator trials in chronic obstructive pulmonary disease
por: Donohue, James F, et al.
Publicado: (2011)

Characterization of Patients with Chronic Obstructive Pulmonary Disease Initiating Single-Inhaler Long-Acting Muscarinic Antagonist/Long-Acting β(2)-Agonist Dual Therapy in a Primary Care Setting in England
por: Requena, Gema, et al.
Publicado: (2022)

Loss of Asthma Control in Pediatric Patients after Discontinuation of Long-Acting Beta-Agonists
por: R. O'Hagan, Adrian, et al.
Publicado: (2012)

Indacaterol: a new once daily long-acting beta(2) adrenoceptor agonist
por: Beeh, Kai M, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_u2beopqnbgnmds72efrdtchjoi